<p>梅多布鲁克财富管理公司在第三季度购买了雅培（NYSE:ABT - 免费报告）的一项新股份，根据该公司在最近向证券交易委员会提交的 13F 表格。该基金购买了 9,270 股该医疗产品制造商的股票，价值约为 1,242,000 美元。雅培在梅多布鲁克财富管理公司的投资组合中占约 1.3%，使其成为该公司第 19 大持仓。</p>
<p>获取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>ABBV 股票：250 美元可能是大幅第三季度盈利超预期后的新底部</li>
</ul>
<p>其他对冲基金最近也调整了对该公司的持股。IMG Wealth Management Inc. 在第二季度将其在雅培的股份增加了 759.1%。IMG Wealth Management Inc. 目前拥有 189 股该医疗产品制造商的股票，价值 26,000 美元，此前在该期间又购买了 167 股。Anfield Capital Management LLC 在第二季度将其在雅培的持股增加了 81.3%。Anfield Capital Management LLC 目前拥有 232 股该医疗产品制造商的股票，价值 32,000 美元，此前在上个季度又收购了 104 股。Delos Wealth Advisors LLC 在第二季度收购了雅培的新股份，价值 32,000 美元。Curio Wealth LLC 在第二季度将其在雅培的持仓增加了 15,250.0%。Curio Wealth LLC 目前拥有 307 股该医疗产品制造商的股票，价值 42,000 美元，此前在该期间又购买了 305 股。最后，Pineridge Advisors LLC 在第二季度将其在雅培的持仓增加了 34.6%。Pineridge Advisors LLC 目前拥有 315 股该医疗产品制造商的股票，价值 43,000 美元，此前在该期间又购买了 81 股。75.18% 的股票由机构投资者和对冲基金持有。</p>
<h2>雅培股票上涨 0.3%</h2>
<p>NYSE:ABT 周五开盘价为 125.45 美元。该公司的 50 日移动平均线为 126.77 美元，200 日移动平均线为 130.27 美元。该公司的市值为 2181.3 亿美元，市盈率为 15.72，市盈增长比率为 2.28，贝塔值为 0.72。雅培的 12 个月低点为 110.86 美元，12 个月高点为 141.23 美元。该公司的债务与股本比率为 0.23，流动比率为 1.70，速动比率为 1.24。</p>
<ul>
<li>雅培十月股价暴跌是买入信号</li>
</ul>
<p>雅培（NYSE:ABT - 获取免费报告）最近于 10 月 15 日发布了其财报。该医疗产品制造商报告第三季度每股收益（EPS）为 1.30 美元，符合分析师的共识预期 1.30 美元。该公司在该季度的收入为 113.7 亿美元，而分析师预期为 114 亿美元。雅培的股本回报率为 17.60%，净利润率为 31.88%。该公司的季度收入较去年同期增长 6.9%。在去年同期，该公司每股收益为 1.21 美元。雅培已将其 2025 财年的指导目标设定为 5.120-5.180 EPS。研究分析师预测雅培在当前财年将发布 5.14 的每股收益。</p>
<h2>雅培增加股息</h2>
<p>该公司还最近宣布了一项季度股息，将于 2 月 13 日（星期五）支付。1 月 15 日（星期四）登记的股东将获得每股 0.63 美元的股息。该股息的除息日为 1 月 15 日（星期四）。这比雅培之前的季度股息 0.59 美元有所增加。这相当于每年 2.52 美元的股息，股息收益率为 2.0%。雅培的股息支付比率目前为 29.57%。</p>
<h2>分析师评级变动</h2>
<ul>
<li>为什么雅培是 2025 年第二季度的买入：增长与收益</li>
</ul>
<p>一些研究分析师最近对 ABT 股票发表了评论。富国银行将雅培的股票目标价从 142.00 美元上调至 146.00 美元，并在 10 月 16 日的研究报告中给予该公司 “增持” 评级。Weiss Ratings 在周一重申了对雅培股票的 “买入（b-）” 评级。Evercore ISI 将雅培的股票目标价从 144.00 美元下调至 142.00 美元，并在 10 月 15 日的研究报告中对该股票给予 “跑赢大盘” 评级。Raymond James Financial 将雅培的股票目标价从 141.00 美元上调至 146.00 美元，并在 10 月 16 日的研究报告中给予该公司 “跑赢大盘” 评级。最后，加拿大皇家银行在 10 月 16 日的报告中重申了 “跑赢大盘” 评级，并对雅培的股票设定了 147.00 美元的目标价。两位分析师给予该股票 “强烈买入” 评级，十七位分析师给予 “买入” 评级，四位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 147.00 美元。</p>
<p><strong>获取我们最新的雅培股票分析</strong></p>
<h2>雅培公司简介</h2>
<p>（免费报告）</p>
<p>雅培是一家全球医疗保健公司，总部位于伊利诺伊州的阿博特公园，开发、制造和销售广泛的医疗产品和服务。雅培成立于 1888 年，业务涵盖多个领域，专注于诊断、医疗设备、营养品和成熟药品。该公司向医院、诊所、实验室、零售商和直接面向消费者的渠道提供旨在诊断、治疗和管理各种健康状况的产品。</p>
<p>在诊断方面，雅培提供实验室和现场检测平台及试剂，用于检测传染病、慢性病和生物标志物；其 Alinity 系列仪器和快速检测解决方案就是这一能力的例子。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，胜过雅培</li>
<li>什么是股息之王？</li>
<li>MarketBeat 周回顾 – 12/15 - 12/19</li>
<li>股票中的跳空上涨意味着什么？如何利用跳空</li>
<li>耐克盈利超预期，但在中国市场面临挑战并遭遇关税</li>
<li>在 52 周高点盈利交易股票</li>
<li>人工智能热潮是泡沫吗？这两只股息股票表示不是</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在雅培吗？</h2>
<p>在考虑雅培之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而雅培并不在名单上。</p>
<p>虽然雅培目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

雅培

<p>Meadowbrook Wealth Management LLC 在第三季度收购了雅培的新股份，购买了 9,270 股，价值约为 1,242,000 美元。这项投资占 Meadowbrook 投资组合的 1.3%。雅培的股票由 75.18% 的机构投资者和对冲基金持有。该公司最近报告了第三季度每股收益为 1.30 美元，并将季度股息提高至每股 0.63 美元。分析师给予了积极的评级，目标价格范围在 142 美元到 147 美元之间</p>

<p>Meadowbrook Wealth Management LLC bought a new stake in Abbott Laboratories (NYSE:ABT - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 9,270 shares of the healthcare product maker's stock, valued at approximately $1,242,000. Abbott Laboratories comprises approximately 1.3% of Meadowbrook Wealth Management LLC's investment portfolio, making the stock its 19th biggest position.</p>
<div class="lb-trans"><p>梅多布鲁克财富管理公司在第三季度购买了雅培（NYSE:ABT - 免费报告）的一项新股份，根据该公司在最近向证券交易委员会提交的 13F 表格。该基金购买了 9,270 股该医疗产品制造商的股票，价值约为 1,242,000 美元。雅培在梅多布鲁克财富管理公司的投资组合中占约 1.3%，使其成为该公司第 19 大持仓。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>ABBV 股票：250 美元可能是大幅第三季度盈利超预期后的新底部</li>
</ul>
</div><p>Other hedge funds also recently modified their holdings of the company. IMG Wealth Management Inc. lifted its stake in shares of Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker's stock valued at $26,000 after buying an additional 167 shares during the period. Anfield Capital Management LLC raised its holdings in Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker's stock valued at $32,000 after acquiring an additional 104 shares during the last quarter. Delos Wealth Advisors LLC acquired a new stake in shares of Abbott Laboratories during the second quarter worth $32,000. Curio Wealth LLC grew its position in shares of Abbott Laboratories by 15,250.0% in the second quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker's stock valued at $42,000 after purchasing an additional 305 shares during the period. Finally, Pineridge Advisors LLC lifted its position in Abbott Laboratories by 34.6% during the second quarter. Pineridge Advisors LLC now owns 315 shares of the healthcare product maker's stock worth $43,000 after buying an additional 81 shares during the period. 75.18% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他对冲基金最近也调整了对该公司的持股。IMG Wealth Management Inc. 在第二季度将其在雅培的股份增加了 759.1%。IMG Wealth Management Inc. 目前拥有 189 股该医疗产品制造商的股票，价值 26,000 美元，此前在该期间又购买了 167 股。Anfield Capital Management LLC 在第二季度将其在雅培的持股增加了 81.3%。Anfield Capital Management LLC 目前拥有 232 股该医疗产品制造商的股票，价值 32,000 美元，此前在上个季度又收购了 104 股。Delos Wealth Advisors LLC 在第二季度收购了雅培的新股份，价值 32,000 美元。Curio Wealth LLC 在第二季度将其在雅培的持仓增加了 15,250.0%。Curio Wealth LLC 目前拥有 307 股该医疗产品制造商的股票，价值 42,000 美元，此前在该期间又购买了 305 股。最后，Pineridge Advisors LLC 在第二季度将其在雅培的持仓增加了 34.6%。Pineridge Advisors LLC 目前拥有 315 股该医疗产品制造商的股票，价值 43,000 美元，此前在该期间又购买了 81 股。75.18% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Abbott Laboratories Trading Up 0.3%</h2>
<div class="lb-trans"><h2>雅培股票上涨 0.3%</h2>
</div><p>NYSE:ABT opened at $125.45 on Friday. The business's 50-day moving average is $126.77 and its two-hundred day moving average is $130.27. The firm has a market capitalization of $218.13 billion, a PE ratio of 15.72, a price-to-earnings-growth ratio of 2.28 and a beta of 0.72. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24.</p>
<div class="lb-trans"><p>NYSE:ABT 周五开盘价为 125.45 美元。该公司的 50 日移动平均线为 126.77 美元，200 日移动平均线为 130.27 美元。该公司的市值为 2181.3 亿美元，市盈率为 15.72，市盈增长比率为 2.28，贝塔值为 0.72。雅培的 12 个月低点为 110.86 美元，12 个月高点为 141.23 美元。该公司的债务与股本比率为 0.23，流动比率为 1.70，速动比率为 1.24。</p>
</div><ul>
<li>Abbott Laboratories' October Price Plunge Is a Signal to Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培十月股价暴跌是买入信号</li>
</ul>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.30. The business had revenue of $11.37 billion during the quarter, compared to analyst estimates of $11.40 billion. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The company's revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.21 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. Research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 获取免费报告）最近于 10 月 15 日发布了其财报。该医疗产品制造商报告第三季度每股收益（EPS）为 1.30 美元，符合分析师的共识预期 1.30 美元。该公司在该季度的收入为 113.7 亿美元，而分析师预期为 114 亿美元。雅培的股本回报率为 17.60%，净利润率为 31.88%。该公司的季度收入较去年同期增长 6.9%。在去年同期，该公司每股收益为 1.21 美元。雅培已将其 2025 财年的指导目标设定为 5.120-5.180 EPS。研究分析师预测雅培在当前财年将发布 5.14 的每股收益。</p>
</div><h2>Abbott Laboratories Increases Dividend</h2>
<div class="lb-trans"><h2>雅培增加股息</h2>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, January 15th. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.59. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.0%. Abbott Laboratories's dividend payout ratio is presently 29.57%.</p>
<div class="lb-trans"><p>该公司还最近宣布了一项季度股息，将于 2 月 13 日（星期五）支付。1 月 15 日（星期四）登记的股东将获得每股 0.63 美元的股息。该股息的除息日为 1 月 15 日（星期四）。这比雅培之前的季度股息 0.59 美元有所增加。这相当于每年 2.52 美元的股息，股息收益率为 2.0%。雅培的股息支付比率目前为 29.57%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>Why Abbott Laboratories Is a Q2 2025 Buy: Growth &amp; Yield</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么雅培是 2025 年第二季度的买入：增长与收益</li>
</ul>
</div><p>A number of research analysts have recently commented on ABT shares. Wells Fargo &amp; Company upped their price objective on shares of Abbott Laboratories from $142.00 to $146.00 and gave the company an &#34;overweight&#34; rating in a research note on Thursday, October 16th. Weiss Ratings restated a &#34;buy (b-)&#34; rating on shares of Abbott Laboratories in a report on Monday. Evercore ISI cut their price target on shares of Abbott Laboratories from $144.00 to $142.00 and set an &#34;outperform&#34; rating on the stock in a research note on Wednesday, October 15th. Raymond James Financial boosted their price objective on shares of Abbott Laboratories from $141.00 to $146.00 and gave the company an &#34;outperform&#34; rating in a research note on Thursday, October 16th. Finally, Royal Bank Of Canada reiterated an &#34;outperform&#34; rating and issued a $147.00 target price on shares of Abbott Laboratories in a report on Thursday, October 16th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $147.00.</p>
<div class="lb-trans"><p>一些研究分析师最近对 ABT 股票发表了评论。富国银行将雅培的股票目标价从 142.00 美元上调至 146.00 美元，并在 10 月 16 日的研究报告中给予该公司 “增持” 评级。Weiss Ratings 在周一重申了对雅培股票的 “买入（b-）” 评级。Evercore ISI 将雅培的股票目标价从 144.00 美元下调至 142.00 美元，并在 10 月 15 日的研究报告中对该股票给予 “跑赢大盘” 评级。Raymond James Financial 将雅培的股票目标价从 141.00 美元上调至 146.00 美元，并在 10 月 16 日的研究报告中给予该公司 “跑赢大盘” 评级。最后，加拿大皇家银行在 10 月 16 日的报告中重申了 “跑赢大盘” 评级，并对雅培的股票设定了 147.00 美元的目标价。两位分析师给予该股票 “强烈买入” 评级，十七位分析师给予 “买入” 评级，四位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 147.00 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Abbott Laboratories</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的雅培股票分析</strong></p>
</div><h2>Abbott Laboratories Profile</h2>
<div class="lb-trans"><h2>雅培公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.</p>
<div class="lb-trans"><p>雅培是一家全球医疗保健公司，总部位于伊利诺伊州的阿博特公园，开发、制造和销售广泛的医疗产品和服务。雅培成立于 1888 年，业务涵盖多个领域，专注于诊断、医疗设备、营养品和成熟药品。该公司向医院、诊所、实验室、零售商和直接面向消费者的渠道提供旨在诊断、治疗和管理各种健康状况的产品。</p>
</div><p>In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.</p>
<div class="lb-trans"><p>在诊断方面，雅培提供实验室和现场检测平台及试剂，用于检测传染病、慢性病和生物标志物；其 Alinity 系列仪器和快速检测解决方案就是这一能力的例子。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>What is a Dividend King?</li>
<li>MarketBeat Week in Review – 12/15 - 12/19</li>
<li>What Does a Gap Up Mean in Stocks? How to Play the Gap</li>
<li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li>
<li>Profitably Trade Stocks at 52-Week Highs</li>
<li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过雅培</li>
<li>什么是股息之王？</li>
<li>MarketBeat 周回顾 – 12/15 - 12/19</li>
<li>股票中的跳空上涨意味着什么？如何利用跳空</li>
<li>耐克盈利超预期，但在中国市场面临挑战并遭遇关税</li>
<li>在 52 周高点盈利交易股票</li>
<li>人工智能热潮是泡沫吗？这两只股息股票表示不是</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在雅培吗？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑雅培之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而雅培并不在名单上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然雅培目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Meadowbrook Wealth Management LLC 收购雅培实验室的新股份 $ABT